Výsledky vyhledávání

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma

Autor: Ghassan K. Abou-Alfa, Kristen Bibeau, Nikolaus Schultz, Amin Yaqubie, Brittanie Millang, Haobo Ren, Luis Féliz

Publikováno v: Targeted Oncology. 17:517-527

First-line standard-of-care therapy for advanced cholangiocarcinoma is gemcitabine plus cisplatin; there is no established second-line systemic therapy. Fibroblast growth factor receptor (FGFR)-2 fusions/rearrangements can be oncogenic drivers, occur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::880765dd44a938c5ca3d8ee5caf95cee
https://doi.org/10.1007/s11523-022-00906-w

Zobrazit plný text záznamu

Data from Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

Autor: Timothy C. Burn, Davide Melisi, Camilla Zecchetto, Luis Féliz, Huiling Zhen, Robert C. Newton, Sherry Owens, Luc Friboulet, Antoine Hollebecque, Ian M. Silverman

Pemigatinib, a selective FGFR1–3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions/rearrangements, and has gained regulatory approval in the United States. Elig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da035ad9df6005abe4dff9fbc887b35c
https://doi.org/10.1158/2159-8290.c.6548233.v1

Zobrazit plný text záznamu

Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response

Autor: Kristen Bibeau, Luis Féliz, Christine F. Lihou, Haobo Ren, Ghassan K. Abou-Alfa

Publikováno v: JCO Precision Oncology.

PURPOSE Oncogenic fibroblast growth factor receptor (FGFR) gene alterations have been described in patients with cholangiocarcinoma (CCA). This post hoc analysis assessed progression-free survival (PFS) in patients who had received first- or second-l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::17d69173d6916cb610a60c81f5cbb8c7
https://doi.org/10.1200/po.21.00414

Zobrazit plný text záznamu

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Autor: Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M. Kas, Frank Rolfs, Catrin Lutz, Jessica K. Lee, Sjoerd Klarenbeek, Ian M. Silverman, Stefano Annunziato, Chang S. Chan, Sander R. Piersma, Timo Eijkman, Madelon Badoux, Ewa Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, Richard R. de Goeij-de Haas, Gregory M. Riedlinger, Hua Ke, Russell Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, Linda Henneman, Martine H. van Miltenburg, Natalie Proost, Huiling Zhen, Ellen Wientjens, Roebi de Bruijn, Julian R. de Ruiter, Ute Boon, Renske de Korte-Grimmerink, Bastiaan van Gerwen, Luis Féliz, Ghassan K. Abou-Alfa, Jeffrey S. Ross, Marieke van de Ven, Sven Rottenberg, Edwin Cuppen, Anne Vaslin Chessex, Siraj M. Ali, Timothy C. Burn, Connie R. Jimenez, Shridar Ganesan, Lodewyk F. A. Wessels, Jos Jonkers

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42007ac1db1800b2f49158a1d120fdb2

Zobrazit plný text záznamu

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Publikováno v: Zingg, Daniel; Bhin, Jinhyuk; Yemelyanenko, Julia; Kas, Sjors M; Rolfs, Frank; Lutz, Catrin; Lee, Jessica K; Klarenbeek, Sjoerd; Silverman, Ian M; Annunziato, Stefano; Chan, Chang S; Piersma, Sander R; Eijkman, Timo; Badoux, Madelon; Gogola, Ewa; Siteur, Bjørn; Sprengers, Justin; de Klein, Bim; de Goeij-de Haas, Richard R; Riedlinger, Gregory M; ... (2022). Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature, 608(7923), pp. 609-617. Springer Nature 10.1038/s41586-022-05066-5
Zingg, D, Bhin, J, Yemelyanenko, J, Kas, S M, Rolfs, F, Lutz, C, Lee, J K, Klarenbeek, S, Silverman, I M, Annunziato, S, Chan, C S, Piersma, S R, Eijkman, T, Badoux, M, Gogola, E, Siteur, B, Sprengers, J, de Klein, B, de Goeij-de Haas, R R, Riedlinger, G M, Ke, H, Madison, R, Drenth, A P, van der Burg, E, Schut, E, Henneman, L, van Miltenburg, M H, Proost, N, Zhen, H, Wientjens, E, de Bruijn, R, de Ruiter, J R, Boon, U, de Korte-Grimmerink, R, van Gerwen, B, Féliz, L, Abou-Alfa, G K, Ross, J S, van de Ven, M, Rottenberg, S, Cuppen, E, Chessex, A V, Ali, S M, Burn, T C, Jimenez, C R, Ganesan, S, Wessels, L F A & Jonkers, J 2022, ' Truncated FGFR2 is a clinically actionable oncogene in multiple cancers ', Nature, vol. 608, no. 7923, pp. 609-617 . https://doi.org/10.1038/s41586-022-05066-5
Nature, 608(7923), 609-617. Nature Publishing Group

Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer1. However, clinical responses to FGFR inhibitors have remained variable1–9, emp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8f8325919e6300d2961522f5a44b67f
https://pubmed.ncbi.nlm.nih.gov/36050473

Zobrazit plný text záznamu

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with

Autor: Tanios S, Bekaii-Saab, Juan W, Valle, Eric, Van Cutsem, Lorenza, Rimassa, Junji, Furuse, Tatsuya, Ioka, Davide, Melisi, Teresa, Macarulla, John, Bridgewater, Harpreet, Wasan, Mitesh J, Borad, Ghassan K, Abou-Alfa, Ping, Jiang, Christine F, Lihou, Huiling, Zhen, Ekaterine, Asatiani, Luis, Féliz, Arndt, Vogel

Publikováno v: Future oncology (London, England). 16(30)

FGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA. Pemigatinib, a selective, potent, oral inhibitor of FGFR1-3, has demonstrated efficacy a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::98e7816bfea37b17ed2bf341f75c4654
https://pubmed.ncbi.nlm.nih.gov/32677452

Zobrazit plný text záznamu

Clinicogenomic Analysis of

Autor: Ian M, Silverman, Antoine, Hollebecque, Luc, Friboulet, Sherry, Owens, Robert C, Newton, Huiling, Zhen, Luis, Féliz, Camilla, Zecchetto, Davide, Melisi, Timothy C, Burn

Publikováno v: Cancer discovery. 11(2)

Pemigatinib, a selective FGFR1-3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::539eca61f55dae2eb78856516e1e0ad3
https://pubmed.ncbi.nlm.nih.gov/33218975

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání